Abstract
Background: The novel water-soluble inclusion complex of Brucea javanica oil (BJO) by β-cyclodextrin polymers (CDP) was prepared by saturated aqueous method and characterized by SEM, FT-IR and 1H NMR. Compared with BJO, the aqueous solubility of BJO-CDP (77.76%) greatly enhanced due to the water-soluble CDP host.
Results: In the acute toxicity test, the value of LD50 of BJO-CDP was 11.94 g/kg, suggesting the lower toxicity of BJO-CDP. Moreover, the pharmacodynamics of BJO-CDP was investigated by evaluating its inhibition effects on human hepatoma SMMC-7721 cells and mice transplantable colon cancer CT- 26 cells.
Conclusion: It has been revealed that BJO-CDP significantly decreased the toxicity of BJO and enhanced its anti-tumor activity. In conclusion, BJO-CDP could be a new and improved clinical formulation of BJO with higher water solubility, lower toxicity and enhanced anti-tumor activity.
Keywords: Brucea javanica oil, β-cyclodextrin polymers, aqueous solubility, acute toxicity test, pharmacodynamics, antitumor.
Graphical Abstract
Current Pharmaceutical Biotechnology
Title:Preparation, Characterization, Toxicity and Pharmacodynamics of the Inclusion Complex of Brucea javanica Oil with β-cyclodextrin Polymers
Volume: 18 Issue: 10
Author(s): Rong-Rong Xu, Rong Hu*, Lin Chen, Bo Pan, Xing-Chen Wang, Huan-Huan Wu and Xian-Hong Song
Affiliation:
- Department of Pharmacy, Medical Academy, Yangzhou University, Yangzhou 225009,China
Keywords: Brucea javanica oil, β-cyclodextrin polymers, aqueous solubility, acute toxicity test, pharmacodynamics, antitumor.
Abstract: Background: The novel water-soluble inclusion complex of Brucea javanica oil (BJO) by β-cyclodextrin polymers (CDP) was prepared by saturated aqueous method and characterized by SEM, FT-IR and 1H NMR. Compared with BJO, the aqueous solubility of BJO-CDP (77.76%) greatly enhanced due to the water-soluble CDP host.
Results: In the acute toxicity test, the value of LD50 of BJO-CDP was 11.94 g/kg, suggesting the lower toxicity of BJO-CDP. Moreover, the pharmacodynamics of BJO-CDP was investigated by evaluating its inhibition effects on human hepatoma SMMC-7721 cells and mice transplantable colon cancer CT- 26 cells.
Conclusion: It has been revealed that BJO-CDP significantly decreased the toxicity of BJO and enhanced its anti-tumor activity. In conclusion, BJO-CDP could be a new and improved clinical formulation of BJO with higher water solubility, lower toxicity and enhanced anti-tumor activity.
Export Options
About this article
Cite this article as:
Xu Rong-Rong, Hu Rong *, Chen Lin , Pan Bo, Wang Xing-Chen, Wu Huan-Huan and Song Xian-Hong, Preparation, Characterization, Toxicity and Pharmacodynamics of the Inclusion Complex of Brucea javanica Oil with β-cyclodextrin Polymers, Current Pharmaceutical Biotechnology 2017; 18 (10) . https://dx.doi.org/10.2174/1389201019666171211153209
DOI https://dx.doi.org/10.2174/1389201019666171211153209 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a ‘New Frontier’?
Anti-Cancer Agents in Medicinal Chemistry Eupatilin Inhibits the Proliferation and Migration of Prostate Cancer Cells through Modulation of PTEN and NF-κB Signaling
Anti-Cancer Agents in Medicinal Chemistry Tea (Camellia sinensis (L.)): A Putative Anticancer Agent in Bladder Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy of Kidney Cancer
Current Clinical Pharmacology Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations
Current Pharmacogenomics and Personalized Medicine Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Hypertension, Antihypertensive Therapy and Renal-Cell Cancer: A Meta-Analysis
Current Drug Safety MicroRNAs in Renal Cell Carcinoma
MicroRNA Emerging Immunotargets in Bladder Cancer
Current Drug Targets Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry The Pattern of Non-AIDS-defining Cancers in the HIV Population: Epidemiology, Risk Factors and Prognosis. A Review
Current HIV Research Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism